logo

For the Inventor, By the Inventor

Auburn, CA, United States of America

Desmond D Mascarenhas

This inventor holds 31 USPTO granted patents and 3 published patent applications, primarily in Biochemical Therapeutics. Top assignees: Celtrix Pharmaceuticals, Inc., Bioexpertise LLC, Ontherix, Inc.. Active years: 1995-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Desmond D Mascarenhas. Retrieved from https://idiyas.com/inventor/desmond-d-mascarenhas

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 

% Patents Active = 77.4

Average Co-Inventor Count = 1.3

ph-index = 13

Forward Citations = 583(Granted Patents)


Location History:

  • Sunnyvale, CA (US) (1997)
  • San Rafael, CA (US) (1995 - 1998)
  • Los Altos, CA (US) (2000)
  • San Jose, CA (US) (2007)
  • Los Altos Hills, CA (US) (1998 - 2013)
  • Auburn, CA (US) (2019)

Company Filing History:

goldMedal15 out of 45 
 
Celtrix Pharmaceuticals, Inc.
 patents
silverMedal5 out of 5 
 
Bioexpertise LLC
 patents
bronzeMedal4 out of 4 
 
Ontherix, Inc.
 patents
4. 4 out of 4 
 
Protigen, Inc.
 patents
5. 1 out of 1 
 
Celtrix Phamraceuticals, Inc.
 patent
6. 2 out of 834,570 
Other
 patents

Years Active: 1995-2019

Loading Chart...
Areas of Expertise:
Epigenetic Stress Response
Therapeutic Peptides
Psychological Disorders
Drug Response Prediction
Insulin-like Growth Factor
Fusion Polypeptides
Biochemical Signatures
Metabolic Disorders
Cancer Treatment
Anonymized Transactions
31 patents (USPTO):Explore Patents
1. 10369191 - Modulation of epigenetic stress response (2019-08-06),
2. 8536135 - Adaptive biochemical signatures (2013-09-17),
3. 8010400 - System and method for using psychological significance pattern information for matching with target information (2011-08-30),
4. 7662624 - Metal-binding therapeutic peptides (2010-02-16),
5. 7618816 - Metal-binding therapeutic peptides (2009-11-17),
6. 7611893 - Metal-binding therapeutic peptides (2009-11-03),
7. 7371813 - Method for use of IGF-binding protein for selective sensitization of target cells in vivo (2008-05-13),
8. 7288516 - Null IGF for the treatment of cancer (2007-10-30),
9. 7213032 - System and method for anonymous transaction in a data network and classification of individuals without knowing their real identity (2007-05-01),
10. 7162432 - System and method for using psychological significance pattern information for matching with target information (2007-01-09),
11. 7058516 - Computer implemented searching using search criteria comprised of ratings prepared by leading practitioners in biomedical specialties (2006-06-06),
12. 6914049 - IGF-binding protein-derived peptide or small molecule (2005-07-05),
13. 6887851 - IGF-binding protein-derived peptide (2005-05-03),
14. 6861406 - IGF-binding protein-derived peptide (2005-03-01),
15. 6808393 - Interactive assessment tool (2004-10-26),

Title: Desmond D Mascarenhas: A Pioneer in Epigenetic Therapeutics

Introduction

Desmond D Mascarenhas, based in Auburn, CA, is an innovative inventor with a remarkable portfolio of 31 patents. His work primarily focuses on the intersection of epigenetics and oxidative stress, offering new insights and therapeutic methods that could profoundly impact medical science.

Latest Patents

One of his latest inventions tackles the modulation of the epigenetic stress response, addressing the serious long-term complications that arise from various forms of stress. This invention introduces a method that utilizes nephrilin peptide, administered through daily subcutaneous bolus injections, to counteract the systemic adverse effects of stress. The significance of this method lies in its capacity to mitigate changes in DNA methylation and histone modifications, which have not been adequately addressed in previous research. Additionally, he has developed methods for generating adaptive biochemical signatures in live cells, aimed at generating diagnostic and therapeutic strategies for human diseases by utilizing provocative agents and measuring adaptive readouts.

Career Highlights

Throughout his career, Mascarenhas has collaborated with notable organizations, including Celtrix Pharmaceuticals, Inc. and Bioexpertise LLC. His innovative approach to epigenetics and therapeutic interventions has led to the development of groundbreaking methodologies that may transform patient outcomes in various medical fields.

Collaborations

In his professional journey, Mascarenhas has worked alongside distinguished coworkers such as Pamela S Olson and David R Olsen, contributing to a dynamic environment of collaborative innovation and research. Together, they have helped advance knowledge in understanding the complexities of stress response and its implications on health.

Conclusion

Desmond D Mascarenhas stands out as a leading figure in the realm of epigenetic research, with a strong emphasis on oxidative stress and its clinical relevance. His contributions through numerous patents illustrate his commitment to advancing medical science and improving human health outcomes, thereby cementing his legacy as a significant inventor in his field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…